Company Information

CIN
Status
Date of Incorporation
15 September 1989
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
07 June 2023
Paid Up Capital
101,500
Authorised Capital
500,000

Directors

Muralidhar Venkata Karanam
Muralidhar Venkata Karanam
Director/Designated Partner
almost 2 years ago
Chand Berry
Chand Berry
Director/Designated Partner
over 2 years ago
Rehan Khan Abbas
Rehan Khan Abbas
Director/Designated Partner
almost 4 years ago

Past Directors

Rajesh Ashok Tendolkar
Rajesh Ashok Tendolkar
Director
about 6 years ago
Vivek Vasudev Kamath
Vivek Vasudev Kamath
Additional Director
over 8 years ago
Sameer Arunkumar Tamhane
Sameer Arunkumar Tamhane
Director
over 12 years ago
Venkatraman Krishnan
Venkatraman Krishnan
Director
over 18 years ago
Rajender Kumar Rustagi
Rajender Kumar Rustagi
Director
over 21 years ago

Patents

Pharmaceutical Formulation Comprising An Antibiotic, A Triazole And A Corticosteriod

The present invention relates to a pharmaceutical composition for the treatment of an infection in an animal comprising an antibiotic or one of its pharmaceutically stable salts; an antifungally effective amount of a pharmaceutically acceptable triazole compound, a corticosteroid and at least one pharmaceutically ac...

A Process For Preparing Oxazolidine Protected Aminodiol Compounds And Their Conversion To Florfenicol

A process for preparing ester oxazolidine compounds is disclosed. These compounds are useful intermediates in processes for making Florfenicol.

A Process For Preparing Oxazolidine Protected Aminodiol Compounds Useful As Intermediates To Florfenicol

An improved method of preparing oxazolidine protected aminodiol compounds is disclosed. These compounds are useful intermediates in processes for making Florfenicol.

An Improved Process For Preparing Oxazolidine Protected Amonodiol Compounds Useful As Intermediates To Florfenicol

An improved method of preparing oxazolidine protected aminodiol compounds is disclosed. These compounds are useful intermediates in processes for making Florfenicol.

Control Of Parasites In Animals By The Use Of Novel Trifluoromethanesulfonanilide Oxime Ether Derivatives

Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.

Pharmaceutical Compositions Comprising Buprenorphine

A method of providing systemic analgesia to cats, dogs and other small mammals by the otic or transdermal administration of opioids is disclosed. Compositions for use in such, a method are also disclosed.

Method For Replicating Influenza Virus In Culture

Abstract METHOD FOR REPLICATING INFLUENZA VIRUS IN CULTURE The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce to tissue-cultural adapted viral isolate. The invention also includes vaccines produced from the isolate.

Canine Thymic Stromal Lymphopoietin Protein And Uses Thereof

Abstract CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and rela...

Effervescent Formulations Of Florfenicol For Addition In Drinking Water Systems

Abstract EFFERVESCENT FORMULATIONS OF FLORFENICOL FOR ADDITION IN DRINKING WATER SYSTEMS The invention relates to an effervescent formulation containing florfenicol or an antibiotic of related structure. When introduced into water, the effervescent formulation s dissolved with minimal or no agitation and provides ...

Pharmaceutical Composition For Treating Inflammation

Abstract PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING INFLAMMATION IN CATTLE AND OTHER ANIMALS Novel transdermal preparations combining a non-steroidal anti¬inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory condit...

A Phosphate Ester Of Florfenicol Having Superior Water Solubility

The present invention discloses phosphate esters of florfenicol (prodrugs) and florfenicol analogs having superior water solubility that are hydrolyzed to florfenicol or the respective florfenicol analog in vivo, upon administration to an animal.

Compositions Microbial And Parasitic Infections In Animals

Novel formulations combining an antiparasitic compounds, such as an avermectin, with a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as Florfenicol are disclosed. Methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bov...

A Novel Growth Differentiation Factor 8 Peptide And A Vaccine Comprising The Same

ABSTRACT The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of tre...

A Composition Containing Flunixin And An Antibiotic Of Formula I

The present invention relates to a novel fonnulation combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, v"ith a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol as disclosed. Methods for using such fonnulations in the treatment and prevention of infectiou...

Neutralising Epitope Based Growth Enhancing Vaccine

The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating anim...

Control Of Parasites In Animals By The Use Of Imixazo(1,2 B) Pyridazine Derivatives

Novel imidazo[1,2-b]pyridazine compounds useful for controlling parasites in animals and methods of treatment of parasite infestation in animals using the compounds are disclosed. Formula (I).

A Process For Preparing Oxazoline Protected Aminodiol Compounds Useful As Intermediates To Florfenicol

A method of preparing oxazoline-protected aminodiol compounds of formula IV is disclosed. These compounds are useful intermediates in processes for preparing Florfenicol and related compounds.

Parasiticidal Composition

A parasiticidal composition The present invention relates to a parasiticidal composition for topical application to an animal consisting essentially of a pyrethroid or a pyrethrin and a carrier; wherein said carrier is selected from the group consisting of a terpene, a terpene derivative, a terpene with an alkyl gl...

A Composition For The Treatment Of Microbial And Parasitic Infection In An Animal

The present invention relates to novel formulations combining an antiparasitic compounds, such as avermectin, with a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as Flofenicol are disclosed. Methods for using such formulations in the treatment and prevention of infectious diseases of bovin...

Recombinant Attenuated Clostridium Organisms And Vaccine

Abstract RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridi...

Carbonates Of Fenicol Antibiotics

The invention relates to carbonate derivatives of fenicol compounds of formulae I and II, wherein the variables are as defined in the claims, having useful properties as antibiotic prodrugs, together with methods of making and using these compounds.

Methods For Continuous Culture Of Obligate Intracellular Protozoa And Protozoa Obtained Thereby

The invention relates to a method of excysting and growing protozoal oocysts by in vitro tissue culture resulting in production of a continuous culture of merozoites. The invention also provides an economical and reliable supply of cultured Eimeria sp. for vaccine production, assays and research. Domesticated avians...

Registered Trademarks

Vettav Scheringplough

[Class : 5] Pharmaceutical Preparations.

Nuflor Scheringplough

[Class : 5] Pharmaceuticals Preparations, Antibiotics For Veterinary Use.

Broilerbron Scheringplough

[Class : 5] Pharmaceutical Preparations For Veterinary Use; Veterinary Vaccines.
View +6 more Brands for Schering Plough (India) Private Limited.

Documents

List of share holders, debenture holders;-17122019
Form MGT-7-17122019_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-18102019
Form DIR-12-18102019_signed
Optional Attachment-(1)-18102019
Optional Attachment-(2)-18102019
Form AOC-4(XBRL)-18102019_signed
Form ADT-1-07102019_signed
Copy of resolution passed by the company-07102019
Copy of written consent given by auditor-07102019
Copy of the intimation sent by company-07102019
Evidence of cessation;-27092019
Notice of resignation;-27092019
Form DIR-12-27092019_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-06092019
Form DIR-12-06092019_signed
Optional Attachment-(1)-06092019
Interest in other entities;-06092019
Form ADT-1-22042019_signed
Copy of resolution passed by the company-22042019
Copy of written consent given by auditor-22042019
List of share holders, debenture holders;-11122018
Form MGT-7-11122018_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-22102018
Form AOC-4(XBRL)-22102018_signed
List of share holders, debenture holders;-20122017
Form MGT-7-20122017_signed
Form DIR-12-25102017_signed
Optional Attachment-(1)-25102017
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-16102017